Anika Therapeutics (ANIK) Operating Margin (2016 - 2025)
Historic Operating Margin for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to 11.62%.
- Anika Therapeutics' Operating Margin fell 113500.0% to 11.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 10.99%, marking a year-over-year decrease of 344900.0%. This contributed to the annual value of 4.25% for FY2024, which is 49500.0% down from last year.
- As of Q3 2025, Anika Therapeutics' Operating Margin stood at 11.62%, which was down 113500.0% from 14.81% recorded in Q2 2025.
- In the past 5 years, Anika Therapeutics' Operating Margin ranged from a high of 24.07% in Q2 2021 and a low of 852.09% during Q4 2023
- Over the past 5 years, Anika Therapeutics' median Operating Margin value was 9.69% (recorded in 2022), while the average stood at 83.55%.
- Its Operating Margin has fluctuated over the past 5 years, first plummeted by -5630900bps in 2022, then soared by 8497800bps in 2024.
- Anika Therapeutics' Operating Margin (Quarter) stood at 25.47% in 2021, then tumbled by -2211bps to 588.55% in 2022, then crashed by -45bps to 852.09% in 2023, then skyrocketed by 100bps to 2.3% in 2024, then tumbled by -404bps to 11.62% in 2025.
- Its Operating Margin was 11.62% in Q3 2025, compared to 14.81% in Q2 2025 and 16.37% in Q1 2025.